Episode 47: ESMO 2026 Commentary: Prostate Cancer
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
-
Letto da:
-
Di:
Rounding out their three-part coverage from the ESMO 2026 Congress in Madrid, Dr. Aly-Khan Lalani and Dr. Christopher Wallis welcome special guest Dr. Sébastien Hotte to explore the latest developments in prostate cancer research and treatment.
The conversation begins with findings from the DASL-HiCaP trial, examining the role of darolutamide alongside androgen deprivation therapy (ADT) and radiation therapy in very high-risk localized prostate cancer. The discussion also revisits the PROTEUS trial, highlighting new data from its surgical substudy, evolving approaches to treatment intensification, and the importance of multidisciplinary collaboration in optimizing patient care.
Turning to emerging therapies, the panel explores promising early findings involving RIPTAC molecules and their novel mechanism of action. They also review updated evidence from PEACE-1 andquality-of-life findings from the PR.21 trial, considering how these advances may shape treatment decisions in metastatic prostate cancer.
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Ferring, Pfizer, Tolmar, AbbVie, Astellas, Ipsen, Merck, Bayer, TerSera.